Developing abuse-proof painkillers
This article was originally published in Start Up
Companies that want to win market share from the new-and-improved Oxycontin, and other widely prescribed opioid analgesics, know they must come up with their own ways of rendering the pain-relieving chemicals resistant to tampering and abuse. The founders of KemPharm Inc. believe they can achieve the goal by synthetically modifying FDA-approved painkilling compounds so that they become prodrugs that release the parent compound only when taken orally.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.